Measurements of multistatic X&L band radar signatures of UAVs

This paper illustrates the results of a series of measurements of multistatic radar signatures of small UAVs at L and X band. The system employed was the multistatic multiband radar system, NeXtRAD, consisting of one monostatic transmitter-receiver and two bistatic receivers. Results demonstrate the capability of the system of recording bistatic data with baselines and two-way bistatic range of the order of few kilometres

Measurements and discrimination of drones and birds with a multi‐frequency multistatic radar system

This article presents the results of a series of measurements of multistatic radar signatures of small UAVs at L‐ and X‐bands. The system employed was the multistatic multiband radar system, NeXtRAD, consisting of one monostatic transmitter‐receiver and two bistatic receivers. NeXtRAD is capable of recording simultaneous bistatic and monostatic data with baselines and two‐way bistatic range of the order of a few kilometres. The paper presents an empirical analysis with range‐time plots and micro‐Doppler signatures of UAVs and birds of opportunity recorded at several hundred metres of distance. A quantitative analysis of the overall signal‐to‐noise ratio is presented along with a comparison between the power of the signal scattered from the drone body and blades. A simple study with empirically obtained features and four supervised‐learning classifiers for binary drone versus non‐drone separation is also presented. The results are encouraging with classification accuracy consistently above 90% using very simple features and classification algorithms

MEG Upgrade Proposal

We propose the continuation of the MEG experiment to search for the charged lepton flavour violating decay (cLFV) \mu \to e \gamma, based on an upgrade of the experiment, which aims for a sensitivity enhancement of one order of magnitude compared to the final MEG result, down to the $6 \times 10^{-14}$ level. The key features of this new MEG upgrade are an increased rate capability of all detectors to enable running at the intensity frontier and improved energy, angular and timing resolutions, for both the positron and photon arms of the detector. On the positron-side a new low-mass, single volume, high granularity tracker is envisaged, in combination with a new highly segmented, fast timing counter array, to track positron from a thinner stopping target. The photon-arm, with the largest liquid xenon (LXe) detector in the world, totalling 900 l, will also be improved by increasing the granularity at the incident face, by replacing the current photomultiplier tubes (PMTs) with a larger number of smaller photosensors and optimizing the photosensor layout also on the lateral faces. A new DAQ scheme involving the implementation of a new combined readout board capable of integrating the diverse functions of digitization, trigger capability and splitter functionality into one condensed unit, is also under development. We describe here the status of the MEG experiment, the scientific merits of the upgrade and the experimental methods we plan to use.Comment: A. M. Baldini and T. Mori Spokespersons. Research proposal submitted to the Paul Scherrer Institute Research Committee for Particle Physics at the Ring Cyclotron. 131 Page

The research on the immuno-modulatory defect of Mesenchymal Stem Cell from Chronic Myeloid Leukemia patients

Overwhelming evidence from leukemia research has shown that the clonal population of neoplastic cells exhibits marked heterogeneity with respect to proliferation and differentiation. There are rare stem cells within the leukemic population that possess extensive proliferation and self-renewal capacity not found in the majority of the leukemic cells. These leukemic stem cells are necessary and sufficient to maintain the leukemia. While the hematopoietic stem cell (HSC) origin of CML was first suggested over 30 years ago, recently CML-initiating cells beyond HSCs are also being investigated. We have previously isolated fetal liver kinase-1-positive (Flk1+) cells carrying the BCR/ABL fusion gene from the bone marrow of Philadelphia chromosome-positive (Ph+) patients with hemangioblast property. Here, we showed that CML patient-derived Flk1+CD31-CD34-MSCs had normal morphology, phenotype and karyotype but appeared impaired in immuno-modulatory function. The capacity of patient Flk1+CD31-CD34- MSCs to inhibit T lymphocyte activation and proliferation was impaired in vitro. CML patient-derived MSCs have impaired immuno-modulatory functions, suggesting that the dysregulation of hematopoiesis and immune response may originate from MSCs rather than HSCs. MSCs might be a potential target for developing efficacious cures for CML

Live cell cytoplasm staining and selective labeling of intracellular proteins by non-toxic cell-permeant thiophene fluorophores

none8noA structurally correlated series of cell-permeant thiophene fluorophores, characterized by intense green or red fluorescence inside live mouse embryonic fibroblasts, was developed. The fluorophores displayed rapid internalization, excellent retention inside the cells, and high optical stability in the cytosolic environment and did not alter cell viability and reproducibility. Depending on the molecular structure, they experienced distinct fate inside the cells: from bright and lasting staining of the cytoplasm to selective tagging of a small set of globular proteins. © The Royal Society of Chemistry 2014.noneDI MARIA, FRANCESCA GIULIA; Palamã , I. E.; Baroncini, Massimo; Barbieri, A.; Bongini, Alessandro; Bizzarri, R.; Gigli, G.; Barbarella, G.DI MARIA, FRANCESCA GIULIA; Palamã , I. E.; Baroncini, Massimo; Barbieri, A.; Bongini, Alessandro; Bizzarri, R.; Gigli, G.; Barbarella, G

Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.

Aim: The lack of sensitivity of chronic myeloid leukemia (CML) stem cells to imatinib mesylate (IM) commonly leads to drug dose escalation or early disease relapses when therapy is stopped. Here, we report that packaging of IM into a biodegradable carrier based on polyelectrolyte microcapsules increases drug retention and antitumor activity in CML stem cells, also improving the ex vivo purging of malignant progenitors from patient autografts. Materials & methods: Microparticles/capsules were obtained by layer-by-layer (LbL) self-assembly of oppositely charged polyelectrolyte multilayers on removable calcium carbonate (CaCO3) templates and loaded with or without IM. A leukemic cell line (KU812) and CD34+ cells freshly isolated from healthy donors or CML patients were tested. Results & discussion: Polyelectrolyte microcapsules (PMCs) with an average diameter of 3 µm, fluorescently labelled multilayers sensitive to the action of intracellular proteases and 95–99% encapsulation efficiency of IM, were prepared. Cell uptake efficiency of such biodegradable carriers was quantified in KU812, leukemic and normal CD34+ stem cells (range: 70–85%), and empty PMCs did not impact cell viability. IM-loaded PMCs selectively targeted CML cells, by promoting apoptosis at doses that exert only cytostatic effects by IM alone. More importantly, residual CML cells from patient leukapheresis products were reduced or eliminated more efficiently by using IM-loaded PMCs compared with freely soluble IM, with a purging efficiency of several logs. No adverse effects on normal CD34+ stem-cell survival and their clonogenic potential was noticed in long-term cultures of hematopoietic progenitors in vitro. Conclusion: This pilot study provides the proof-of-principle for the clinical application of biodegradable IM-loaded PMC as feasible, safe and effective ex vivo purging agents to target CML stem cells, in order to improve transplant outcome of resistant/relapsed patients or reduce IM dose escalation